When it comes to battling cancer, early detection is crucial. A recent article from The Guardian discussed a new blood test that aims to change the way we screen for early stage tumors, especially in high risk patients over the age of 50. The test is called Galleri, and it was developed by Grail, a company focused on detecting cancer early when it’s more treatable or even curable.
Galleri was developed using a machine learning algorithm and works by examining changes in DNA that was shed from tumors and is circulating in the bloodstream. It will be piloted by NHS England this fall, and the results of the 140,000 participants are expected by 2023.